As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges
Growing number of products participating in BsUFA program, coupled with budgetary challenges, have made FDA attainment of some early goals under the Biosimilar User Fee Act difficult.
You may also be interested in...
New unit could help better coordinate policy, operations and other biosimilar functions, FDA tells industry.
Agency's biosimilar meeting workload rose slightly; shifts in types of meetings may reflect maturation of individual biosimilar development programs.
As user fee negotiations begin, FDA has far more sponsors in product development phase and far fewer marketing applications than anticipated.